Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Jessica Merrill

New York, NY
Jessica Merrill is a Bureau Editor for US Commercial Content for Informa’s pharmaceutical news publications, including “The Pink Sheet” and SCRIP. She has been covering the pharmaceutical industry as a journalist for more than 10 years, spanning the spectrum from R&D to regulatory to commercial. She was previously a reporter and editor for “The Pink Sheet” and “Pink Sheet” DAILY, specializing in business and commercial news, focusing largely on big pharma, M&A and business development, and the commercial landscape, including drug launches and market access. Before embarking on a career in healthcare journalism, she covered business news for the cosmetics industry and worked as a newspaper reporter.
Set Alert for Articles By Jessica Merrill

Latest From Jessica Merrill

Sanofi, Longtime Leader In Diabetes, Is Exiting Diabetes Research

The company's decision to exit diabetes research is not necessarily surprising given the development and commercial challenges in the therapeutic area, but it's not insignificant either.

Metabolic Disorders Cardiovascular

Merck & Co. Joins Competitive BTK Research Space With $2.7bn ArQule Buy

ArQule's lead candidate, ARQ 531, is a novel BTK inhibitor in Phase II development that could work in patients with B-cell malignancies resistant to existing BTK inhibitors like Imbruvica.

Deals M & A

Pfizer's Bourla: "I Think We Forgot What It Looks Like To Grow"

The big pharma CEO reflected on his first year of leadership at Pfizer during the Forbes Healthcare Summit and talked about executing on a plan to deliver 6% growth through 2026. 
Leadership Growth

Ardelyx Plans Mid-2020 NDA Filing For Tenapanor In Hyperphosphatemia

The company reported positive Phase III data from a second trial testing the first-in-class therapy as monotherapy for managing hyperphosphatemia in patients on dialysis.
Financing Business Strategies

IFM Therapeutics ‘Lather, Rinse, Repeat’ Strategy On Track With $55M Financing

The drug discovery company with a big pharma deal-making track record is launching a new subsidiary, IFM Quattro, and a drug discovery incubator, IFM Discovery. Scrip talked to IFM's new CEO Martin Seidel about what is ahead for the company.

Financing Innovation

It Has Been A Long Farewell To The Medicines Company

The company Novartis is buying for $9.7bn is largely unrecognizable from the one Clive Meanwell started in 1996, grew into a multi-product hospital specialist and began to sunset in 2015 with the loss of Angiomax.

Companies Business Strategies
See All
UsernamePublicRestriction

Register